Lilly has announced two separate research collaborations with the Dana-Farber Cancer Institute and the Sarah Cannon Research Institute ramping up its early-stage oncology efforts.
The US group is hooking into the Dana-Farber under a three-year pact to research new medicines in development for cancer.
Under the deal, the Institute will provide R&D expertise for a number of early-stage Lilly oncology compounds and work alongside the company’s scientists on a range of preclinical and clinical work. Dana-Farber scientists are also allowed to carry out independent studies on select Lilly compounds.
“Together, we can bring compounds to clinical trials and to FDA approval quickly and efficiently, and thus benefit our patient population,” said the cancer centre’s chief executive Barrett Rollins.
The partnership between Lilly and clinical research organisation the Sarah Cannon Research Institute will see the groups co_develop the investigational oncology compound LY3023414, a PI3K/mTOR dual inhibitor.
The deal supports the development of this novel targeted cancer therapy, including flexible and efficient program design and implementation, as well as more rapid patient enrolment to clinical trials by accessing SCRI’s large network of patients, Lilly said.
